

Luxembourg, 23 December 2025

Environmental and Social Completion Sheet (ESCS)¹

Overview

Project Name:	INVENTIVA - (EGFF)
Project Number:	2021-0353
Country:	France
Project Description:	Inventiva is a late-stage clinical-stage biopharmaceutical company. The scope of the project was to support the development of a treatment for NASH and other fibrotic diseases as well as treatments for other conditions such as lysosomal storage disorder and various cancers. The investments covered predominantly R&D costs to bring the assets closer to the market authorisation and commercialisation.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

No significant environmental issues were noted during the implementation of the project.

Due to the nature of the activity carried out by the Promoter and the number of clinical trials opened and in operation for the Pipeline development, the Project has generated positive societal impact considering the availability of additional therapy options for patients with serious or life-threatening diseases.

Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the Promoter that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.

¹ The template is for ILs and FLs